Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(LORazepam)
4,565 results
  • Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms. [Case Reports]
    Ment Health Clin 2019; 9(5):331-335Bixby AL, Goldsborough S, … VandenBerg A
  • Drug rash with eosinophilia and systemic symptoms (DRESS) is a serious adverse drug reaction with a high mortality rate. Discontinuation of the causative agent is the primary treatment. History of DRESS may put patients at higher risk of future episodes; however, cross-reactivity between various medications is not well established. An 18-year-old African American male with a history of bipolar I …
  • Active Anti-Inflammatory and Hypolipidemic Derivatives of Lorazepam. [Journal Article]
    Molecules 2019; 24(18)Theodosis-Nobelos P, Papagiouvannis G, … Rekka EA
  • Novel derivatives of some non steroidal anti-inflammatory drugs, as well as of the antioxidants α-lipoic acid, trolox and (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid with lorazepam were synthesised by a straightforward method at satisfactory to high yields (40%-93%). All the tested derivatives strongly decreased lipidemic indices in rat plasma after Triton induced hyperlipidaemia. They …
  • Catatonia in patients with dementia: a case report. [Case Reports]
    Pan Afr Med J 2019; 33:117Younes S, Khouadja S, … Zarrouk L
  • Catatonia occurring as part of a clinical picture of dementia has been reported with almost all types of dementia. It remains under-diagnosed in older adults and those with dementia. We review a case of a young patient admitted in our psychiatric department for catatonia and after efficient treatment with Lorazepam, assessment revealed a dementia. Catatonia is a severe neuropsychiatric syndrome w…
  • The Use of Rapid Tranquilization in Aggressive Behavior. [Journal Article]
    Dtsch Arztebl Int 2019; 116(26):445-452Hirsch S, Steinert T
  • CONCLUSIONS: All of these drugs, if accepted by the patient, can also have an additional, beneficial placebo effect, with the patient calming down more rapidly than could be explained on pharmacological grounds alone. It is, therefore, important in emergencies (as at other times) for the patient to be involved in treatment decisions to the greatest possible extent.
  • Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. [Review]
    Cochrane Database Syst Rev 2019; 8:CD006570Zaman H, Gibson RC, Walcott G
  • CONCLUSIONS: Analysis of the results from this review, which was a head-to-head comparison of two benzodiazepine monotherapies, does not show a clear difference in effect. No data were available for benzodiazepines compared to placebo or standard care. The lack of usable data and very low quality of data available makes it impossible to draw firm conclusions and further studies with a high-quality methodology and reporting are required in order to determine more definitively the outcomes associated with benzodiazepine use in the clinical management of catatonia in persons with schizophrenia and other SMI.
New Search Next